Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled Phase IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and Preliminary Efficacy of SGC001 Injection in Participants With Predicted Severe Acute Pancreatitis.

NCT07803965 is registered in ClinicalTrials.gov with Beijing Sungen Biomedical Technology Co., Ltd as lead sponsor.

NCT NCT07803965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07803965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled Phase IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and Preliminary Efficacy of SGC001 Injection in Participants With Predicted Severe Acute Pancreatitis.
Lead sponsor
Beijing Sungen Biomedical Technology Co., Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
September 30, 2026
Completion date
January 31, 2028
Enrollment
129 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

acute pancreatitis